

- **Name:** Bhumsuk Keam
 - **Current Position & Affiliation:** Clinical professor
Department of Internal Medicine, Seoul National University Hospital
 - **Country:** Republic of Korea
-

- **Educational Background:**

- Mar. 1998- Feb. 2002: Seoul National University College of Medicine, Seoul, Korea
- Sep. 2004- Feb.2007: Degree of Master in Medicine, Seoul National University College of Medicine, Seoul, Korea
- Mar.2007- Aug.2014: Ph.D. in Medicine Seoul National University College of Medicine, Seoul, Korea

- **Professional Experience:**

- Mar. 2002- Feb. 2003: Internship, Seoul National University Hospital, Seoul, Korea
- Mar. 2003- Feb. 2007: Residency Course at Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- May 2010-Feb. 2011: Clinical Fellow, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- Mar. 2011- Feb. 2015: Clinical Assistant Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- Mar. 2015- Feb 2020: Clinical Associate Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- Mar. 2020- Present: Clinical Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

- **Professional Organizations:**

- Mar. 2004- Present: Korean Cancer Study Group, Full Member
- May 2005- Present: Korean Society for Hospice and Palliative Care, Full Member
- Apr. 2006- Present: Korean Association for Clinical Oncology, Full Member
- Sep. 2006- Present: American Society of Clinical Oncology, Active Member
- Feb. 2008- Present: Korean Association of Internal Medicine, Full Member
- Sep.2008- Present: European Society for Medical Oncology, Full Member
(ESMO faculty member for the Head and Neck Cancer faculty group for the period 2019-2023)
- Apr.2012-Present: International Association for the Study of Lung Cancer, Member
- Nov.2012- Present: American Association of Cancer Research, Member
- Feb.2016- Present Korean Society for Medical Ethics, Member

• Main Scientific Publications:

- 1) Sharma P, Sohn J, Shin SJ, Oh DY, **Keam B**, Lee HJ, Gizzi M, Kalinka E, de Vos FYFL, Ruscica D, Ferro S, Xiao F, Baverel P, Chen CC, Asubonteng K, Morsli N, Dirix L. Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. *Clin Cancer Res.* 2020 Jan 1;26(1):61-70.
- 2) **Keam B**, Lee KW, Lee SH, Kim JS, Kim JH, Wu HG, Eom KY, Kim S, Ahn SH, Chung EJ, Kwon SK, Jeong WJ, Jung YH, Kim JW, Heo DS. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. *Oncologist.* 2019 Jun;24(6):751-e231.
- 3) Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, **Keam B**, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. *Cancer Discov.* 2018 Jul;8(7):812-821.
- 4) Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, **Keam B**. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. *J Clin Oncol.* 2018 Jan 1;36(1):7-13.
- 5) Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, **Keam B**, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. *J Clin Oncol.* 2016 Sep 19.
- 6) Ock CY, **Keam B**, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T cell infiltration. *Clin Cancer Res.* 2016 May 1;22(9):2261-70